Oxidative stress represents one of the most fundamental and early pathogenic mechanisms in neurodegenerative diseases, including [Alzheimer's disease](/diseases/alzheimers-disease) (AD), [Parkinson's disease](/diseases/parkinsons-disease) (PD), Amyotrophic Lateral Sclerosis (ALS), and Huntington's disease (HD)[@butterfield2023][@dias2023]. Defined as an imbalance between the production of [reactive oxygen species](/entities/reactive-oxygen-species) (ROS) and the cellular antioxidant defense capacity, oxidative stress contributes to neuronal dysfunction and death through multiple pathways, including lipid peroxidation, protein oxidation, DNA damage, and mitochondrial dysfunction[@prez2024][@fischer2023]. The brain is particularly vulnerable to oxidative damage due to its high metabolic rate, elevated oxygen consumption, and relatively limited antioxidant capacity compared to other organs[@cobley2023].
Oxidative stress represents one of the most fundamental and early pathogenic mechanisms in neurodegenerative diseases, including [Alzheimer's disease](/diseases/alzheimers-disease) (AD), [Parkinson's disease](/diseases/parkinsons-disease) (PD), Amyotrophic Lateral Sclerosis (ALS), and Huntington's disease (HD)[@butterfield2023][@dias2023]. Defined as an imbalance between the production of [reactive oxygen species](/entities/reactive-oxygen-species) (ROS) and the cellular antioxidant defense capacity, oxidative stress contributes to neuronal dysfunction and death through multiple pathways, including lipid peroxidation, protein oxidation, DNA damage, and mitochondrial dysfunction[@prez2024][@fischer2023]. The brain is particularly vulnerable to oxidative damage due to its high metabolic rate, elevated oxygen consumption, and relatively limited antioxidant capacity compared to other organs[@cobley2023].
The role of oxidative stress in neurodegeneration has evolved from being considered a secondary consequence of other pathological processes to a primary driver of disease initiation and progression[@gandhi2022]. Evidence demonstrates that oxidative damage precedes the appearance of classic pathological hallmarks such as [amyloid-beta](/proteins/amyloid-beta) plaques, neurofibrillary tangles, or [alpha-synuclein](/proteins/alpha-synuclein) inclusions, suggesting that oxidative stress may be an early upstream event that initiates or accelerates downstream pathological cascades[@keller2024][@nunomura2023]. This understanding has significant therapeutic implications, as antioxidant therapies could potentially prevent or slow disease progression if administered early in the disease process.
The mitochondria represent the primary cellular source of ROS, generating superoxide anion (O2•-) as a byproduct of normal oxidative phosphorylation[@murphy2023][@trewavas2024]. Complex I (NADH dehydrogenase) and Complex III (ubiquinol-cytochrome c reductase) of the electron transport chain (ETC) are the main sites of superoxide production during normal respiration[@finkel2023]. Under physiological conditions, approximately 0.2-2% of oxygen consumed by mitochondria is partially reduced to form superoxide, which is then converted to hydrogen peroxide (H2O2) by superoxide dismutase (SOD)[@chance2024].
In neurodegenerative diseases, mitochondrial dysfunction leads to increased ROS production through multiple mechanisms[@lin2024]. Mutations in mitochondrial DNA (mtDNA) accumulate with age and are enhanced in AD and PD, leading to defective ETC components that produce more superoxide[@wallace2023]. Impaired complex activities (particularly Complex I in PD and Complex IV in AD) create electron leak and enhance ROS generation[@parker2023]. Additionally, damaged mitochondria have reduced efficiency of the ETC, further increasing electron leak and ROS production in a vicious cycle of oxidative damage and mitochondrial dysfunction[@cadenas2024].
NADPH oxidases represent another major source of ROS in the brain, particularly in glial cells and [neurons](/entities/neurons)[@bedard2023][@sorce2024]. Originally discovered in phagocytic cells as a host defense mechanism, NOX enzymes are now known to be expressed in neurons and glia where they produce ROS in response to various stimuli[@lettre2023]. The NOX2 isoform is highly expressed in [microglia](/cell-types/microglia-neuroinflammation) and is activated by amyloid-beta, leading to ROS production that contributes to neuroinflammation and neuronal damage in AD[@bianca2024].
In Parkinson's disease, NOX activation in dopaminergic neurons contributes to oxidative stress and cell death[@wu2023]. The NOX1 isoform is expressed in neurons and can be activated by various pathological stimuli, including aggregated alpha-synuclein[@zhang2024]. NOX-derived ROS can also activate inflammatory signaling pathways, creating a feed-forward loop between oxidative stress and neuroinflammation that amplifies neuronal damage[@kaemmerer2023].
Brain metal ion dyshomeostasis, particularly of iron, copper, and zinc, contributes significantly to oxidative stress in neurodegeneration[@crichton2024][@ayton2023]. Transition metals can catalyze the production of highly reactive hydroxyl radicals (•OH) through the Fenton reaction, where reduced metals (Fe2+ or Cu+) react with hydrogen peroxide to produce •OH and the oxidized metal form[@halliwell2024]. This reaction is particularly damaging because •OH is the most reactive ROS and attacks lipids, proteins, and DNA with near diffusion-limited rate constants.
In Alzheimer's disease, elevated iron and copper levels colocalize with amyloid-beta plaques, and the interaction between these metals and A beta promotes ROS generation[@smith2023]. Iron accumulation in the substantia nigra is a characteristic finding in Parkinson's disease and is believed to contribute to the selective vulnerability of dopaminergic neurons[@zecca2024]. The iron-binding protein ferritin is elevated in neurodegenerative diseases, reflecting a cellular response to increased iron and oxidative stress[@fischbach2023].
Activated microglia and infiltrating immune cells produce ROS through NOX enzymes and other mechanisms, contributing to oxidative stress in the neurodegenerative environment[@heneka2024][@nimmerjahn2023]. In AD, amyloid-beta activates microglia via pattern recognition receptors (including TLRs and CD36), leading to ROS production that exacerbates neuronal damage[@bolmont2024]. The chronic inflammatory state in neurodegenerative diseases creates a sustained source of ROS from activated glial cells.
In Parkinson's disease, microglia are activated by neuromelanin (released from dying dopaminergic neurons) and alpha-synuclein aggregates, leading to sustained ROS production that contributes to progressive neuronal loss[@zhang2023]. This neuroinflammatory component of oxidative stress creates spatial amplification of damage beyond the initial site of pathology.
Cells possess multiple enzymatic antioxidant systems to neutralize ROS and maintain redox homeostasis[@ghezzi2024][@ray2023]. Superoxide dismutase (SOD) converts superoxide to hydrogen peroxide, with three isoforms: cytosolic Cu/Zn-SOD (SOD1), mitochondrial Mn-SOD (SOD2), and extracellular SOD (SOD3)[@valentine2024]. Mutations in SOD1 are responsible for approximately 20% of familial ALS cases, demonstrating the critical importance of this enzyme for neuronal survival[@rosen2023].
Catalase and glutathione peroxidases (GPx) convert hydrogen peroxide to water[@fridovich2024]. Catalase is particularly important in peroxisomes, while GPx uses reduced glutathione (GSH) as an electron donor to reduce peroxides, producing oxidized glutathione (GSSG)[@arthur2023]. The glutathione system is crucial for neuronal antioxidant defense, and GSH levels are reduced in AD, PD, and other neurodegenerative conditions[@aoyama2024]. Glutathione reductase recycles GSSG back to GSH, maintaining the reduced glutathione pool necessary for continuous antioxidant function[@mannervik2023].
Non-enzymatic antioxidants provide additional protection against oxidative damage[@pisoschi2024]. Vitamin E (alpha-tocopherol) is the most important lipid-soluble antioxidant, protecting cell membranes from lipid peroxidation[@brigeliusflohe2023]. Vitamin E levels are reduced in AD and PD brains, and supplementation has been explored as a therapeutic strategy with mixed results[@socci2024]. Vitamin C (ascorbic acid) is the major water-soluble antioxidant in the brain and can regenerate oxidized vitamin E[@rice2023].
Coenzyme Q10 (ubiquinone) is a mitochondrial antioxidant that also functions in electron transport[@giacometti2024]. Reduced CoQ10 levels have been reported in PD and AD, and CoQ10 supplementation has shown some promise in clinical trials for neurodegenerative diseases[@shults2023]. The carotenoid antioxidants (lutein, zeaxanthin, beta-carotene, beta-cryptoxanthin) and the flavonoid class of plant-derived antioxidants also contribute to neuronal antioxidant defense[@mares2024].
Lipid peroxidation is particularly damaging in the brain due to its high lipid content[@nunn2024][@esterbauer2023]. Membrane phospholipids undergo radical chain reactions initiated by •OH, producing lipid hydroperoxides (LOOH) and reactive aldehydes such as 4-hydroxynonenal (4-HNE) and malondialdehyde (MDA)[@sayre2024]. These lipid peroxidation products form covalent adducts with proteins, further amplifying cellular damage and interfering with normal protein function[@uchida2023].
In Alzheimer's disease, lipid peroxidation is elevated in vulnerable brain regions and correlates with disease severity[@montine2024]. 4-HNE modifies key proteins involved in energy metabolism, antioxidant defense, and [tau](/proteins/tau) phosphorylation, contributing to multiple aspects of the pathogenic cascade[@nunomura2023a]. Lipid peroxidation products also activate stress-sensitive signaling pathways and can trigger [apoptosis](/entities/apoptosis)[@zhang2024a]. In Parkinson's disease, lipid peroxidation is elevated in the substantia nigra and is believed to contribute to dopaminergic neuron vulnerability[@dexter2023].
Oxidative modification of proteins alters their structure and function, contributing to neuronal dysfunction[@dalledonne2024][@stadtman2023]. Carbonylation (introduction of carbonyl groups into amino acid side chains) is a irreversible oxidative modification that marks proteins for degradation but can also impair function when it occurs in essential proteins[@grimsrud2024]. Protein carbonyls are elevated in AD, PD, and other neurodegenerative conditions, and the pattern of carbonylation reveals which proteins are most affected[@castegna2023].
Specific proteins damaged by oxidation in neurodegeneration include: mitochondrial enzymes (leading to energy failure), antioxidant enzymes (reducing cellular defense), and signaling proteins (disrupting normal cellular communication)[@choudhary2024]. The oxidation of enzymes such as glutamine synthetase in AD impairs astrocytic function and glutamate cycling, contributing to excitotoxicity[@givvimani2023].
Oxidative DNA damage accumulates in neurodegenerative diseases through multiple mechanisms[@kelley2024][@mller2023]. The base excision repair (BER) pathway handles most oxidative DNA lesions, including 8-oxoguanine (8-oxoG), the most common oxidative DNA damage product[@krokan2024]. 8-oxoG mispairs with adenine during DNA replication, causing G:C to T:A transversion mutations if not repaired.
In AD, oxidative DNA damage is elevated in neurons and correlates with the earliest cognitive changes[@wang2023]. The base excision repair capacity is reduced in AD, impairing the removal of oxidative lesions and leading to their accumulation[@copped2024]. In PD, mitochondrial DNA (mtDNA) accumulates mutations at a higher rate than nuclear DNA due to proximity to ROS sources and limited repair capacity, contributing to the progressive decline of mitochondrial function[@picca2023].
Mitochondrial dysfunction and oxidative stress form a vicious cycle in neurodegeneration[@nunnari2024][@liu2023]. ROS damage mitochondrial components including ETC proteins, cardiolipin, and mtDNA, impairing mitochondrial function and increasing ROS production[@mitochondrial2024]. Damaged mitochondria have reduced ATP production, leading to energy failure and impaired cellular homeostasis[@schapira2023].
The permeability transition pore (PTP) is a mitochondrial channel whose opening is promoted by oxidative stress, leading to mitochondrial membrane potential loss, release of pro-apoptotic factors (cytochrome c, AIF), and activation of the intrinsic apoptotic pathway[@bernardi2024]. This mechanism is believed to be important in the progressive neuronal loss that characterizes neurodegenerative diseases[@kroemer2023].
The recognition of oxidative stress as a key pathogenic mechanism has driven the development of antioxidant-based therapeutic strategies[@giacomelli2024][@kim2023]. Direct antioxidants such as vitamin E, vitamin C, and CoQ10 have been tested in clinical trials for AD and PD with mixed results[@lloret2024]. The failure of many antioxidant trials may reflect: (1) insufficient antioxidant potency; (2) inadequate brain penetration; (3) timing of intervention (too late in disease course); or (4) complex pro-oxidant effects of some antioxidants in specific contexts[@bjelakovic2023].
More sophisticated approaches target specific sources of ROS rather than global antioxidant supplementation[@cai2024]. NOX inhibitors (e.g., apocynin, GKT137831) are being developed for neurodegenerative diseases based on the role of NOX in ROS production and neuroinflammation[@cao2023]. Mitochondria-targeted antioxidants such as MitoQ (coenzyme Q10 attached to a triphenylphosphonium cation for mitochondrial accumulation) and SS-31 (a peptide that targets cardiolipin) have shown promise in preclinical models[@murphy2024].
Given the role of metal dyshomeostasis in oxidative stress, strategies to restore normal metal handling have been explored[@bush2023]. Chelation therapy to remove excess iron has been tested in PD and AD, with some positive results but also concerns about removing essential metal ions[@devos2024]. Metal-protein-attenuating compounds (MPACs) such as clioquinol bind to metal ions while preserving normal metal homeostasis and have shown benefit in clinical trials for AD[@bush2023a].
Rather than providing exogenous antioxidants, approaches to boost the cell's own antioxidant systems may be more effective[@johnson2024]. Nrf2 (nuclear factor erythroid 2-related factor 2) is the master regulator of antioxidant gene expression, activating transcription of genes encoding phase II detoxifying enzymes, antioxidant proteins, and glutathione synthesis enzymes[@kensler2023]. Nrf2 activators such as dimethyl fumarate (approved for multiple sclerosis) are being tested in neurodegenerative diseases[@linker2024].
Oxidative stress is a central mechanism in the pathogenesis of neurodegenerative diseases, acting both as an early trigger of pathology and as a contributor to disease progression through multiple downstream effects. The brain's vulnerability to oxidative damage, combined with the multiple sources of ROS and the limited regenerative capacity of neurons, creates a perfect storm that drives progressive neuronal dysfunction and death. Understanding the specific sources and effects of oxidative stress in each disease context is enabling the development of more targeted therapeutic approaches. While simple antioxidant supplementation has largely failed as a disease-modifying therapy, more sophisticated strategies targeting specific ROS sources, metal homeostasis, and endogenous antioxidant pathways offer promise for future development.
The therapeutic potential of antioxidants in neurodegenerative diseases has been extensively studied, though clinical translation has proven challenging[@rice2023]. Direct antioxidants such as vitamin E and vitamin C have shown mixed results in clinical trials, likely due to their limited ability to target the specific ROS/RNS species and cellular compartments involved in neurodegeneration[@giacometti2024].
More promising approaches include mitochondria-targeted antioxidants such as MitoQ (mitoquinone) and SS-31 (elamipretide), which concentrate in mitochondria and directly scavenge ROS at the site of production[@shults2023]. These compounds have shown neuroprotective effects in preclinical models of AD and PD.
The transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2) is the master regulator of antioxidant response genes[@mares2024]. Under basal conditions, Nrf2 is sequestered in the cytoplasm by Keap1. Upon oxidative stress, Nrf2 translocates to the nucleus and activates expression of antioxidant and cytoprotective genes including HO-1, NQO1, and GCLM.
Pharmacological Nrf2 activators including bardoxolone methyl and dimethyl fumarate have been investigated in neurodegenerative diseases[@nunn2024]. However, the systemic effects of Nrf2 activation raise concerns about potential adverse effects on cell proliferation.
Enhancing the activity of endogenous antioxidant systems represents an attractive therapeutic strategy[@esterbauer2023]. Compounds that increase GSH levels, such as N-acetylcysteine (NAC) and glutathione analogs, have shown promise in preclinical models. Similarly, increasing SOD or catalase activity through gene therapy or small molecules may provide neuroprotective effects.
Oxidative stress biomarkers in blood and cerebrospinal fluid can provide insights into disease status and progression[@sayre2024]. Common peripheral markers include 8-OHdG (8-hydroxy-2'-deoxyguanosine) for DNA oxidation, 4-HNE (4-hydroxynonenal) for lipid peroxidation, and protein carbonyls for protein oxidation. Elevated levels of these markers have been documented in AD, PD, and related disorders.
Advanced imaging techniques allow in vivo visualization of oxidative stress in the brain[@uchida2023].磁共振光谱学 (MRS) can detect altered levels of antioxidant metabolites. Additionally, PET radiotracers targeting oxidative stress markers are under development.
The clinical utility of oxidative stress biomarkers remains an area of active investigation[@montine2024]. While elevated oxidative stress markers are consistently observed in neurodegenerative diseases, their specificity is limited. Biomarker panels that combine oxidative stress markers with other disease-specific markers may improve diagnostic accuracy.
Given the complexity of oxidative stress in neurodegeneration, precision approaches that target specific pathways may be more effective[@nunomura2023a]. This includes developing antioxidants that target particular ROS/RNS species, cellular compartments, or disease-specific mechanisms.
Combining antioxidants with other disease-modifying therapies may provide synergistic benefits[@zhang2024a]. For example, combining antioxidants with anti-amyloid or anti-tau therapies could address multiple pathological hallmarks simultaneously.
Lifestyle interventions that reduce oxidative stress may delay neurodegeneration[@dexter2023]. Regular physical exercise, caloric restriction, and diets rich in antioxidants have been associated with reduced neurodegenerative disease risk and cognitive preservation in aging.
Interactive diagram showing Oxidative Stress's key relationships in the SciDEX knowledge graph (15 connections shown).
The following diagram shows the key molecular relationships involving Oxidative Stress in Neurodegeneration discovered through SciDEX knowledge graph analysis: